简介：QigongisapartoftraditionalChinesemedicine.Accordingtotheantiquetreaties,thefoundationsoftraditionalChinesemedicinearebasedinmaintainingtheharmonybetweenQi(energy),Jing(essence)andShen(spirit).Alterationsinthisharmonycandevelopanddeterminetheappearanceofdisease.TherapeuticeffectsofQigongarehelpfulinthepreventionandtreatmentofseveraldiseases.It'smainroleinrestoringbodyfunctionsisduetothecommunicationbetweeninternalorgans,tissuesandcells.ThemaingoalofthisworkistoshowtheefficacyofQigonginthetreatmentofadermatologicaldiseasecharacterizedbytheappearanceofcircularorovalpatchesofmissinghair,knownasalopeciauniversalis.Forwesternmedicinetheexactcauseofthisillnessisnottotallyrevealed,however,it'sattributedtopsycological,geneticsandmetabolicalterations.FromthetraditionalChinesemedicineperspective,hairalterationsareframedintheareaofthewaterenergy,representedbythekidneyorgan.TheresultsofQigongtreatmentsuggestedthatthecranialhairfollicleshadbeenactivatedsincethefirsttreatment.Astreatmentprogressed,thecranialhairfolliclescontinuedtogrow,what'smore,thebrightnessandpigmentationofthehairalsoincreased.Therefore,intheclinicalconditionsevaluated,Qigongcouldbeaneffectivealternativetreatmentinconsiderationofthevisibleevidenceaboutrapidandlonglastingresults.Besides,wedidnotobserveanysideeffectsofQigonginthiscase.

简介：AbstractPurpose:This study was designed to compare the clinical efficacy of "8" and "0" wire fixation systems combined with double-head cannulated compression screws or Kirschner wires for the treatment of transverse patellar fractures.Methods:From September 2011 to September 2018, patients with closed transverse patellar fractures treated with a double-head compression screw or Kirschner wire were included and analyzed retrospectively. Patients with patellar fractures combined with distal femoral fractures, tibial plateau fracture or preoperative lower limb dysfunction were excluded. The patients treated with the "8" tension band wire fixation system and Kirschner wire were taken as Group A; those treated with the "0" fixation system and Kirschner wire were taken as Group B; those treated with the "8" fixation system and double-head cannulated compression screw were taken as group C; and those treated with the "0" fixation system and double-head cannulated compression screw were taken as group D. Six weeks and one year after the operation and every month from the third month after the operation until the fractures healed, an X-ray examination was performed to identify fracture healing. The time of fracture healing and postoperative complications of the four groups were compared. One year after the operation, knee function was evaluated by Bostman’s score.Results:During the study period, 168 patients with patellar fractures were treated by operations, and 88 patients were excluded because the fracture type did not meet the requirements or because there were combined fractures of the distal femur or tibial plateau. As a result, 80 patients were included in this study, 20 in each group. All the patients were followed up for an average period of 12.2 months. Compared with Group A, patients in Group D presented less postoperative discomfort in the prepatellar region, quicker fracture healing, less fixation failure and better postoperative knee function scores (all p < 0.05). The incidence of internal fixation failure in Group (B+D) was lower than that in Group (A+C) (p > 0.05).Conclusion:The "0" wire fixation system combined with a double-head cannulated compression screw seems to be more beneficial than the other three fixation systems for the treatment of transverse patellar fractures.

简介：AbstractImportance:Recurrent respiratory tract infection (RRTI) is common in children. Inappropriate RRTI treatment will lead to asthma and other diseases, thereby seriously affecting the growth and physical health of children. Immune function modulation can prevent and alleviate childhood RRTI. Yupingfeng (YPF), a patented traditional Chinese medicine (TCM), has immunomodulatory effects and is widely used in China to treat children with RRTI.Objective:To evaluate the safety and efficacy of YPF monotherapy in treating children with RRTI.Methods:This multicenter, randomized, double-blind, double-simulation, noninferiority clinical trial was conducted from January 2015 to August 2017, with an 8-week treatment period and 52-week follow-up after the drug withdrawal. Children aged 2–6 years with RRTI meeting the inclusion and exclusion criteria were enrolled in 13 hospitals in China and divided randomly into three groups (2:2:1 ratio) to receive YPF, pidotimod, or placebo. The primary outcome was the proportion of RRTI returning to normal standard level during the follow-up. The secondary outcomes were reduction in the number of RRTI recurrences, effect on clinical symptoms (in accord with TCM practice), effect per symptom, and safety. The trial was registered at the Chinese Clinical Trials Registry (www.chictr.org.cn) under the unique identifier ChiCTR-IPR-15006847.Results:Three hundred and fifty-one children were enrolled and randomly assigned to 3 groups; 124, 125, and 61 children in the YPF, pidotimod, and placebo groups, respectively, had completed the trial. During the follow-up, the proportion of RRTI returning to normal standard level was 73.13%, 67.15%, and 38.81% with YPF, pidotimod, and placebo, respectively (P < 0.0001). The proportion of cases who returned to normal standard level in the YPF group was 34.32% higher than that in the placebo group. The safety profile did not significantly differ among the groups.Interpretation:YPF granules were noninferior to the active control drug pidotimod oral solution for the treatment of RRTI in children, and were superior to placebo, with a high safety profile.

简介：无

简介：客观：观察膜dialyzer在临床的维护hemodialysis(MHD)由长期的肾的失败病人使用了的polyethersulfone的安全和功效。方法：从1月到2009年2月，36个病人从加盟上海JiaoTong的新华医院被招募大学医学院。实验被人种的委员会同意，新华医院并且在从病人的权限下面。所有病人被使随机化进polyethersulfone组(足，n=18)并且polysulfone组(PS，n=18)。Hemodialysis被使用Fresenius4008S给控制能力的dialyser和极端净化酸式碳酸盐透析液，超过3.5h每次，三次每星期，由肝磷脂antieoagulation列在后面一个星期，三次完全。在血脲氮(甜面包)的变化，浆液creatinine(Scr)，磷酸盐(P2+)，血红素和白朊层次为功效和安全评估被决定。结果：显著地与不同dialyzers在hemodialysis以后减少的浆液甜面包，Scr和P2+集中，和二个组的减少振幅是相等的(P>0.05)。浆液甜面包和重量的单位的清理率没在二个组之中有重要差别(P>0.05)。浆液P2+的清理率(ml/min)是144.57

简介：我们试图与BPH在在正常、肥胖的病人之间的征兆的良性的prostatic增生(BPH)的医疗的功效调查差别；肥胖被任何一个身体团索引(BMI)或腰圆周(WC)决定。在这12星期的未来的观察研究，175个病人的一个总数变老≥；有国际前列腺症状分数(IPSS)≥的40年；12点和前列腺体积≥；20 ；ml有希望地被注册。病人根据BMI或WC被划分成二个组。病人们收到了doxazosin在4 的剂量的胃肠的治疗学的系统(GITS)；mg一次每为12个星期的天。从在IPSS的基线的变化，最大的尿流动率(Q最大),虚空以后的剩余体积，生活(QoL)的质量分数和不利事件(AE)被分析。175个注册病人，132完成了学习。57个病人有BMI>；23 ；kgm−2,和43有的WC>；90 ；厘米。肥胖的病人由WC>代表了；90 ；厘米或BMI≥；23 ；kgm−2在基线与非肥胖的病人相比有显著地更大的前列腺体积。全部的IPSS在WC>是显著地更高的；90 ；与WC≤相比的厘米组；90 ；厘米组。全部的IPSS断然与前列腺体积(P=0.031)和WC(P=0.045)被相关。所有组在12个星期在全部的IPSS和QoL显示出重要改进。然而，全部的IPSS的改进在high-BMI和high-WC组是更大的。最经常的AE是头昏(n=13)，并且它在肥胖的BPH病人是显著地更低的。肥胖与增加的前列腺体积和更低的尿道症状被联系。Alpha-blockers看起来为控制症状有效，特别在肥胖的人。

简介：因为输精管切除术的不可避免的复杂并发症，这研究被承担与一个微型外科的方法与没有解剖刀输精管切除术(NSV)相比植入进管腔的一台nonobstructiveintravas设备(IVD)估计男消毒的功效和安全。IVD被分成二种类型：而，IVD-B让一条尾巴使用了修理到管deferens(固定翅膀)IVD--A不做。multicenter未来的使随机化的控制临床的审判在中国被进行。学习由寻求输精管切除术的1459个男志愿者组成随机被分到IVD--一(n=487)，IVD-B(n=485)或NSV(n=487)组并且经历了操作。包括的后续在3rd-6th和12th手术后的月。对这些题目的评价包含了常规物理考试(包括的将军和andrological考试)和精液分析。subjects’；搭挡们也经历了监视因为由月刊的怀孕关于月经会见，如果必要，尿测试。处于怀孕率没有重要差别(0.65%为IVD--一，0为IVD-B并且0.21%为NSV)在三个组之中(P>；0.05)。在12th手术后的月分别地在三个组是零，0.9%和1.7%。在结论，IVD男消毒展出长期的不利事件的低风险并且被发现作为一个男消毒方法有效，类似于NSV技术。IVD男消毒被期望是一个新奇避孕方法。

简介：

简介：AbstractObjective:Emetine, an isoquinoline alkaloid that is enriched at high concentrations in the lung, has shown potent in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study was to better understand the effectiveness of low-dose emetine for patients with coronavirus disease 2019 (COVID-19).Methods:In this real-world study, 63 patients with mild or common COVID-19 were recruited from Wuhan Fangcang Shelter Hospital and five COVID-19-designated hospitals in Anhui Province, China from February to March 2020. Thirty-nine patients from Wuhan Fangcang Shelter Hospital were assigned to a pragmatic randomized controlled clinical trial, and 24 patients from the 5 COVID-19-designated hospitals in Anhui Province underwent a real-world study. The medication course of emetine was less than 10 days. The main symptoms and adverse reactions of all patients were observed and recorded. The primary outcome measure was the time required for a negative SARS-CoV-2 RNA result or the negative result rate on day 10. Secondary outcomes included axillary temperature, transcutaneous oxygen saturation, and respiratory frequency recovery. The study was approved by the Ethics Committee of The First Affiliated Hospital of Anhui Medical University on February 20, 2019 (approval No. PJ2020-03-19) and was registered with the Chinese Clinical Trial Registry on February 20, 2019 (registration number: ChiCTR2000030022).Results:The oxygen saturation values were higher in the treatment group than in the control group on the first day after enrollment for patients treated at Fangcang Shelter Hospital. The axillary body temperature, respiratory rate, and oxygen saturation among patients in Fangcang Shelter Hospital were related to the time effect but not to the intervention measures. The respiratory rate and oxygen saturation of patients in the Anhui designated hospitals were related to the intervention measures but not to the time effect. The axillary body temperature of patients in Anhui designated hospitals was related to the time effect but not to the intervention measures.Conclusion:Our preliminary study shows that low-dose emetine combined with basic conventional antiviral drugs improves clinical symptoms in patients with mild and common COVID-19 without apparent adverse effects, suggesting that moderately increased doses of emetine may have good potential for treatment and prevention of COVID-19.

简介：BackgroundLeftbundlebranchblock(LBBB)resultsinanalteredpatternofleftventricular(LV)activationandsubsequentcontraction.CardiacsynchronyandcardiacfunctionaredeterioratedbyLBBB.However,theeffectofLBBBhistoryonprogressiveheartdysfunctionandclinicalefficacyofcardiacresynchronizationtherapy(CRT)insuchpatientsarenotclear.InthisstudyweexploretheclinicalefficacyandpredictorofcardiacresynchronizationtherapyinLBBBheartdysfunction.MethodsTwenty-sevenLBBBpatientswithsevereheartfailureweretreatedwithCRT.Twenty-sixLBBBpatientswithoutCRTservedascontrol.During6monthsfollow-up,ECG,plasmaNT-proBNPandechocardiogramindexesweremeasured.ResultsComparedwithbaseline,NYHAfunctionalclassof23patients(85.2%)wasimprovedinCRTgroup.Comparedwithbaselineandcontrol,QRSduration(QRSd)wassignificantlymorenarrow(P=0.023,P=0.019),NT-proBNPwassignificantlylower(P=0.011,P=0.009),ventricularseptaltoleftventricularposteriorwalldelaytimeandleftventriculardyssynchronyindex(Ts-SD)weresignificantlyworse(P<0.05);leftventricularejectionfraction,leftventricularend-systolicvolume,mitralregurgitationareaweresignificantlyimprovedinCRTgroup(P<0.05).whentheLBBBhistorywas≥2yearsandQRSd≥155ms,thesensitivityandspecificityofCRTsuper-responsewere53.4%and85.6%respectively.ConclusionsCRTcanimprovethesynchronizationandhemodynamicofLBBBpatientswithheartdysfunction,theLBBBhistory≥2yearsandQRSd≥155msareoneoftheCRTsuper-responsepredictors.

简介：无

简介：AbstractBackground:Nitinol-containing devices are widely used in clinical practice. However, there are concerns about nickel release after nitinol-containing device implantation. This study aimed to compare the efficacy and safety of a parylene-coated occluder vs. a traditional nitinol-containing device for atrial septal defect (ASD).Methods:One-hundred-and-eight patients with ASD were prospectively enrolled and randomly assigned to either the trial group to receive a parylene-coated occluder (n = 54) or the control group to receive a traditional occluder (n = 54). The plugging success rate at 6 months after device implantation and the pre- and post-implantation serum nickel levels were compared between the two groups. A non-inferiority design was used to prove that the therapeutic effect of the parylene-coated device was non-inferior to that of the traditional device. The Cochran-Mantel-Haenszel chi-squared test with adjustment for central effects was used for the comparison between groups.Results:At 6 months after implantation, successful ASD closure was achieved in 52 of 53 patients (98.11%) in both the trial and control groups (95% confidence interval (CI): [-4.90, 5.16]) based on per-protocol set analysis. The absolute value of the lower limit of the 95% CI was 4.90%, which was less than the specified non-inferiority margin of 8%. No deaths or severe complications occurred during 6 months of follow-up. The serum nickel levels were significantly increased at 2 weeks and reached the maximum value at 1 month after implantation in the control group (P < 0.05 vs. baseline). In the trial group, there was no significant difference in the serum nickel level before vs. after device implantation (P > 0.05).Conclusions:The efficacy of a parylene-coated ASD occluder is non-inferior to that of a traditional uncoated ASD occluder. The parylene-coated occluder prevents nickel release after device implantation and may be an alternative for ASD, especially in patients with a nickel allergy.

简介：在这回顾的研究，我们与先进前列腺癌症在中国病人独自评估了并且比较最大的雄激素封锁(MAB)对阉割的功效和毒性。从1996～2004，有先进前列腺癌症的608个病人在学习被包括。病人们回顾地根据不同治疗学的政体被划分成二个组。608个病人，300个病人与MAB(加nonsteroidalantiandrogens的阉割)并且留下被对待308独自与阉割被对待。这些病人的2年、5年的全面幸存率分别地是73.7%和56%。Multivariate分析证明在有变形前列腺癌症的病人，MAB与没有前进的幸存(PFS)的改进被联系不仅(到10个月增加了)而且在死亡风险的20.6%减小与阉割相比独自一个。相反，MAB的功效不比为有nonmetastatic前列腺癌症的病人独自一个的阉割优异。在有MAB的病人之中，有趣地，那些使用的bicalutamide用flutamide比那些有更长的PFS；这是特别在有变形前列腺癌症的病人。几乎所有毒性，由于荷尔蒙，治疗对温和中等、可管理。得出结论在中国，荷尔蒙治疗，包括的MAB和阉割独自一个，是为先进前列腺癌症的标准治疗。为有nonmetastatic前列腺癌症的病人，阉割可能独自足够地实际、有效。在有变形前列腺癌症的病人，然而，MAB独自在阉割上有优异功效。MAB应该与变形前列腺癌症为病人被认为首要的标准治疗，是清楚的。

简介：AbstractBackground:Helicobacter pylori (HP) has been considered to be one of the primary causes of gastric mucosa-associated lymphoid tissue (MALT) lymphoma since 1993. Low-grade gastric MALT lymphoma with HP is widely treated with HP eradication therapy, according to each specific clinical situation. However, several studies and guidelines indicate that the modified HP eradication therapy is also valid for HP-negative gastric MALT lymphoma. The aim of this study was to perform a meta-analysis of the clinical efficacy of the modified HP eradication therapy for gastric MALT lymphoma without HP.Methods:We searched studies that reported the response rate of the modified HP eradication therapy regimen for gastric MALT lymphoma without HP by using PubMed, Medline, and Ebsco from January 1971 until February 2019. All statistical analyses were carried out using R 3.5.3 (Mathsoft Company, Cambridge, MA, USA). The pooled response rate was expressed as a decimal. The heterogeneity test was performed using the I-squared (I2) statistic.Results:A total of 14 studies were selected with a total of 148 patients with HP-negative gastric MALT lymphoma. The overall pooled response rate was 0.38 (95% confidence interval [CI]: 0.29-0.47). The combined estimate is I2 = 57% (P < 0.01). The study subjects were categorized by factors (area of patients). The pooled response rate of the sub-groups (Korea, Japan, China, and Western countries) was 0.63 (95% CI: 0.50-0.76), 0.16 (95% CI: 0.05-0.30), 0.38 (95% CI: 0.20-0.55), and 0.57 (95% CI: 0.08-1.00). The response rate showed that the modified HP eradication therapy was effective for patients with HP-negative gastric MALT lymphoma, especially in Korea and Western countries.Conclusion:Therefore, the modified HP eradication therapy can be considered an optional therapy for patients with low-grade HP-negative gastric MALT lymphoma. However, several limitations were revealed in the meta-analysis. Further systematic reviews and research are required.

简介：无

简介：AbstractBackground:The Shexiang Baoxin Pill (MUSKARDIA) has been used for treating coronary artery disease (CAD) and angina for more than 30 years in China. Nevertheless, methodologically sound trials on the use of MUSKARDIA in CAD patients are scarce. The aim of the study is to determine the effects of MUSKARDIA as an add-on to optimal medical therapy (OMT) in patients with stable CAD.Methods:A total of 2674 participants with stable CAD from 97 hospitals in China were randomized 1:1 to a MUSKARDIA or placebo group for 24 months. Both groups received OMT according to local tertiary hospital protocols. The primary outcome was the occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke. Secondary outcomes included all-cause mortality, non-fatal MI, non-fatal stroke, hospitalization for unstable angina or heart failure, peripheral revascularization, angina stability and angina frequency.Results:In all, 99.7% of the patients were treated with aspirin and 93.0% with statin. After 2 years of treatment, the occurrence of MACEs was reduced by 26.9% in the MUSKARDIA group (MUSKARDIA: 1.9% vs. placebo: 2.6%; odds ratio = 0.80; 95% confidence interval: 0.45-1.07; P = 0.2869). Angina frequency was significantly reduced in the MUSKARDIA group at 18 months (P = 0.0362). Other secondary endpoints were similar between the two groups. The rates of adverse events were also similar between the two groups (MUSKARDIA: 17.7% vs. placebo: 17.4%, P = 0.8785).Conclusions:As an add-on to OMT, MUSKARDIA is safe and significantly reduces angina frequency in patients with stable CAD. Moreover, the use of MUSKARDIA is associated with a trend toward reduced MACEs in patients with stable CAD. The results suggest that MUSKARDIA can be used to manage patients with CAD.Trial registration:chictr.org.cn, No. ChiCTR-TRC-12003513

简介：Acupuncture,asacomplementarytherapy,hasbeenusedtomanagethecancerassociatedsymptomsofcancerpatients.Toidentifytheefficacyandsafetyofacupunctureinthemanagementofcancer,thisreviewcriticallyanalysestherelevantpublicationsincludingbothexperimentalandclinicalstudies.Themajorityofstudiessuggestthatacupunctureeffectivelyrelievessomecancerrelatedsymptomssuchascancerpain,andsomeadverseeffectscausedbythecancerconventionaltreatmentssuchasnausea,vomiting,neutropeniaandxerostomia.

简介：Whyundertakeclinicaltrials?Beforeanewtreatmentcanbewidelyusedonpatients,itmustbeproventobesafeandeffective.Clinicaltrialsareumeansofconductingexperimentsonhumanstoyieldreliableresults.Forthisreason,theyareinthebestinterestsofpatients,clinicians,pharmaceuticalcompaniesandsocietyasawbele.

简介：无

简介：ObjectivesToevaluatethesafetyandefficacyoftransradialcoronaryprocedures(TRCP).MethodsThedataof83caseswhoacceptedtransradialcoronaryangiography(CAG)andtransradialpercutaneouscoronaryintervention(PCI)inourdepartmentweresummarized.Thesuccessrates,proximalcoronarycomplications,peripheralvascularcomplications,severevagalreflex,meanoperationtime(MOT),meanrecumbenttime(MRT),meanhospital-stayingtime(MHT)wereanalyzed.Thedatawerecomparedwiththatof420casesoftransfemoralcoronaryprocedures(TFCP)inthesameperiod.ResultsSuccessratesandproximalcoronarycomplicationsweresimilarinbothgroups.SeverevagalreflexeswerelessinTRCPgroupthaninTFCPgroup.MOTwaslongerinTRCPgroup.MRTandMHTwereshorterinTRCPgroup.12(14.5%)radialarteryspasm,3(3.6%)radialarteryobstruction,1suddenrespiratoryarrestcausedbyjugularhematomawereobservedinTRCPgroup.ConclusionsTheefficacyandsafetyofTRCParedefinite.TRCPismoreeconomical.ForthepurposeofproperlyevaluatetheperipheralvascularcomplicationsofTRCP,itisnecessarytopayspecialattentiontoradialarteryocclusion,radialarterystenosis,andjugularhematoma.